Friday, 18 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14425
Articles
Company
Deals
Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy
January 29, 2025
Company
Deals
Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics
January 29, 2025
Company
Deals
Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform
January 29, 2025
Company
Deals
GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
January 29, 2025
Company
Drug
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
January 29, 2025
Company
Drug
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
January 29, 2025
Company
Drug
SciClone’s Danyelza Approved for Marketing in China by NMPA
January 29, 2025
Company
Drug
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
January 29, 2025
Company
Deals
Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development
January 29, 2025
Company
Deals
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
January 29, 2025
Company
Deals
Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology
January 29, 2025
Company
Deals
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
January 29, 2025
1
2
…
1,075
1,076
1,077
1,078
1,079
…
1,202
1,203
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?